Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

About this update from Insight Molecular Diagnostics Inc.

[{"type":"image","alt":"Insight Molecular Diagnostics Inc.","displaySize":"","headline":null,"caption":"Insight Molecular Diagnostics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a9omE9cBUejfoy9a_jJadQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4","width":300,"height":114}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenting on GraftAssureIQ at symposium on Thursday, October 9th at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting","length":152,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":338,"olType":false},{"type":"text","content":"NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced attendance at two key industry conferences where it will discuss its GraftAssure™ technology, including its clinical kitted test under development.","length":276,"tagName":"p"},{"type":"text","content":"At the 23rd IATDMCT annual meeting, which is being held September 21st to 24th in Singapore, iMDx will host a symposium to discuss the growing clinical applications of transplant rejection testing into longitudinal surveillance and therapeutic response monitoring, and the benefits of in-house testing.","length":302,"tagName":"p"},{"type":"text","content":"The symposium will highlight how GraftAssure, which is iMDx’s flagship transplant rejection testing technology, can be used to detect transplant rejection, as well as to monitor treatment response in patients. The presentation will also include previously published data showcasing how iMDx’s flagship transplant rejection testing technology significantly reduces time-to-rejection diagnosis in certain high-risk kidney transplant patients.","length":440,"tagName":"p"},{"type":"text","content":"“Kidney transplant management is changing. Emerging medications s...

More updates from Insight Molecular Diagnostics Inc.